Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maraviroc + raltegravir + emtricitabine + tenofovir disoproxil fumarate
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a four-drug combination antiretroviral therapy for HIV-1 infection. It combines: * Maraviroc: A CCR5 co-receptor antagonist that blocks HIV entry into CD4 cells * Raltegravir: An integrase strand transfer inhibitor (INSTI) that prevents HIV DNA integration * Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) * Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor (NtRTI) This combination provides a multi-targeted approach to HIV treatment by blocking viral entry (maraviroc), preventing viral DNA integration (raltegravir), and inhibiting viral replication (emtricitabine and tenofovir disoproxil fumarate).
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCCR5 (C-C chemokine receptor type 5)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on maraviroc + raltegravir + emtricitabine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maraviroc + raltegravir + emtricitabine + tenofovir disoproxil fumarate.